Does WGX50 protect against doxorubicin-induced cardiotoxicity?
WGX50 is a promising drug candidate for cardioprotection against doxorubicin-induced cardiotoxicity by inhibiting mitochondrial ROS and ferroptosis.
Taken together, WGX50 protects DOX-induced cardiotoxicity via mitochondrial ROS and the ferroptosis pathway, which provides novel insights for WGX50 as a promising drug candidate for cardioprotection.
Tai et al. (Fri,) studied this question.